Truist raised the firm’s price target on Alnylam (ALNY) to $535 from $459 and keeps a Buy rating on the shares ahead of its Q3 results. The firm has increased its Q3 Amvuttra sales estimate to $690M and also revised its forward estimates higher to reflect carry through from the strong early adoption and more rapid adoption as a first line agent than previously expected based on feedback from prescribers in the quarter who indicated extracardiac manifestations of ATTR-CM are more widespread than previously appreciated, the analyst tells investors in a research note.
-
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALNY:
